BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by numbness, tingling, and shooting/burning pain. This analysis was performed to describe the relationship between numbness, tingling, and shooting/burning pain in patients with CIPN, as reported using the EORTC QLQ-CIPN20 (CIPN20). METHODS: Baseline CIPN20 data were provided for all patients on a prospective trial designed to treat patients with bothersome CIPN. Baseline frequencies for the items on the CIPN20 are primarily described by descriptive statistics and histograms, with correlational analyses between individual items. RESULTS: A majority of the 199 patients accrued to this study reported "quite a bit" to "very much" numbness (57%) or tingling (63%) in the hands compared to "a little" or "not at all" (numbness (43%), tingling (38%)). Fewer patients reported "quite a bit" to "very much" shooting/burning pain in the hands (18%). Numbness and tingling in the hands were highly correlated (r = 0.69), while neither were highly correlated with shooting/burning pain. Similar results were observed in the feet. More severe ratings for tingling and shooting/burning pain were ascribed to the lower extremities, as opposed to the upper extremities. CONCLUSIONS: In patients with CIPN, severe sensory neuropathy symptoms (numbness, tingling) commonly exist without severe neuropathic pain symptoms (shooting/burning pain), while the reverse is not common. Symptoms in the feet should be evaluated distinctly from those in the hands as the experience of symptoms is not identical, for individual patients, in upper versus lower extremities.
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by numbness, tingling, and shooting/burning pain. This analysis was performed to describe the relationship between numbness, tingling, and shooting/burning pain in patients with CIPN, as reported using the EORTC QLQ-CIPN20 (CIPN20). METHODS: Baseline CIPN20 data were provided for all patients on a prospective trial designed to treat patients with bothersome CIPN. Baseline frequencies for the items on the CIPN20 are primarily described by descriptive statistics and histograms, with correlational analyses between individual items. RESULTS: A majority of the 199 patients accrued to this study reported "quite a bit" to "very much" numbness (57%) or tingling (63%) in the hands compared to "a little" or "not at all" (numbness (43%), tingling (38%)). Fewer patients reported "quite a bit" to "very much" shooting/burning pain in the hands (18%). Numbness and tingling in the hands were highly correlated (r = 0.69), while neither were highly correlated with shooting/burning pain. Similar results were observed in the feet. More severe ratings for tingling and shooting/burning pain were ascribed to the lower extremities, as opposed to the upper extremities. CONCLUSIONS: In patients with CIPN, severe sensory neuropathy symptoms (numbness, tingling) commonly exist without severe neuropathic pain symptoms (shooting/burning pain), while the reverse is not common. Symptoms in the feet should be evaluated distinctly from those in the hands as the experience of symptoms is not identical, for individual patients, in upper versus lower extremities.
Authors: Debra L Barton; Edward J Wos; Rui Qin; Bassam I Mattar; Nathan Benjamin Green; Keith S Lanier; James Dewitt Bearden; John W Kugler; Kay L Hoff; Pavan S Reddy; Kendrith M Rowland; Mike Riepl; Bradley Christensen; Charles L Loprinzi Journal: Support Care Cancer Date: 2010-05-25 Impact factor: 3.603
Authors: M Eileen Dolan; Omar El Charif; Heather E Wheeler; Eric R Gamazon; Shirin Ardeshir-Rouhani-Fard; Patrick Monahan; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Chunkit Fung; Jeri Kim; Sophie D Fossa; Daniel L Hertz; Taisei Mushiroda; Michiaki Kubo; Lawrence H Einhorn; Nancy J Cox; Lois B Travis Journal: Clin Cancer Res Date: 2017-06-13 Impact factor: 12.531
Authors: Loretta A Williams; Araceli Garcia-Gonzalez; Tito R Mendoza; Shireen Haq; Charles S Cleeland Journal: Support Care Cancer Date: 2018-08-10 Impact factor: 3.603
Authors: Matthew R Trendowski; Omar El-Charif; Mark J Ratain; Patrick Monahan; Zepeng Mu; Heather E Wheeler; Paul C Dinh; Darren R Feldman; Shirin Ardeshir-Rouhani-Fard; Robert J Hamilton; David J Vaughn; Chunkit Fung; Christian Kollmannsberger; Taisei Mushiroda; Michiaki Kubo; Robyn Hannigan; Frederick Strathmann; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis; M Eileen Dolan Journal: Clin Cancer Res Date: 2019-07-11 Impact factor: 12.531
Authors: P Alberti; E Rossi; D R Cornblath; I S J Merkies; T J Postma; B Frigeni; J Bruna; R Velasco; A A Argyriou; H P Kalofonos; D Psimaras; D Ricard; A Pace; E Galiè; C Briani; C Dalla Torre; C G Faber; R I Lalisang; W Boogerd; D Brandsma; S Koeppen; J Hense; D Storey; S Kerrigan; A Schenone; S Fabbri; M G Valsecchi; G Cavaletti Journal: Ann Oncol Date: 2013-11-19 Impact factor: 32.976
Authors: Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith Journal: Semin Oncol Nurs Date: 2019-04-30 Impact factor: 2.315
Authors: Deirdre R Pachman; Rui Qin; Drew K Seisler; Ellen M L Smith; Andreas S Beutler; Lauren E Ta; Jacqueline M Lafky; Nina D Wagner-Johnston; Kathryn J Ruddy; Shaker Dakhil; Nathan P Staff; Axel Grothey; Charles L Loprinzi Journal: J Clin Oncol Date: 2015-08-17 Impact factor: 44.544
Authors: Tito R Mendoza; Xin Shelley Wang; Loretta A Williams; Qiuling Shi; Elisabeth G Vichaya; Patrick M Dougherty; Sheeba K Thomas; Emre Yucel; Christel C Bastida; Jeanie F Woodruff; Charles S Cleeland Journal: J Pain Date: 2015-07-22 Impact factor: 5.820